PIK3CA and neoplasm: As expected, BMP7v in combination with taselisib significantly reduced the size of tumor xenografts generated by the injection of PIK3CA-mutated CR-CSCs (Fig. 5c), suggesting the necessity to simultaneously add a PI3K inhibitor in the presence of enhanced activation of the PI3K/AKT pathway.